Natural product-derived therapy for Diabetic Kidney disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 23/June/2017, 9.39 am

Acupuncture-based PD-1 pathway activation for Pain therapy: Acupuncture therapy increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gen, 22/June/2017, 11.37 pm
June 22, 2017
Natural product-derived Anti-AXL therapeutics for enhancing the efficacy of chemotherapies: Combination of Hyperoside and Epigallocatechin-3- gallate, found in Drosera rotundifolia and Green tea, respectively, decreases the expression of the AXL receptor and its activating ligand, GAS6, increases the expression of a number of tumor suppressor genes, increases therapeutic index of anticancer drugs, suppresses tumorigenesis, migration, invasion, and metastasis via up regulation of its target gene, 23/June/2017, 9.49 pm
June 23, 2017
Show all

Introduction: What they say

A study from the Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden shows that “Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.” This research paper was published in the 9 February 2017 issue of the journal “Cell Metabolism” [One of the best research journals in “Metabolism” with an I.F of 17.565] by Prof. Ulf Eriksson and Annelie Falkevall and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Diabetic Kidney disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene

price-300


Significance of the study:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) diabetic disease results in a number of health complications, including diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy; (4) one third of people with diabetes suffer from diabetic kidney disease (DKD); and one third of them will develop kidney failure; (5) life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a way to remove accumulation of lipid in different tissues, such as skeletal muscle, heart, liver and kidney, that improve insulin signalling and sensitivity; (iii) a cheaper alternative to the existing expensive weight-loss drugs; (iv) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, diabetes.


What is known?

Prof.Ulf Erickson’s research team has recently shown that inhibition of VEGF-B in mice results in:(1) reduction of renal lipotoxicity; (2) increased insulin signalling in Podocytes; (3) inhibition of DKD-associated symptoms and pathophysiologies; and (4) amelioration of renal dysfunction. Further, they have shown that patients with DKD have increased levels of VEGF-B, suggesting that decreasing the expression of VEGF-B in DKD patients may alleviate DKD.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based therapy for DKD. Methyl Jasmonate (MeJA), by increasing the expression of its target gene, it may decrease the expression of VEGF-B. Thereby, it may: (1) decrease lipid accumulation in kidneys; (2) increase insulin signalling in Podocytes; (3) improve DKD-associated pathophysiologies, such as proteinuria; and (4) ameliorate kidney dysfunction (Fig.1).

Figure 1 Mechanistic insights into how Methyl Jasmonate (MeJA)  ameliorates Diabetic kidney disease (DKD)

Thus, pharmacological formulations encompassing “Methyl Jasmonate (MeJA)  or its analogues, either alone or in combination with other drugs” may be used to treat DKD.

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Methyl Jasmonate (MeJA) decrease the expression of VEGF-B to prevent DKD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for Diabetic Kidney disease: Methyl Jasmonate (MeJA), isolated from Jasmine, decreases VEGF-B expression, inhibits lipid accumulation in Podocytes, promotes insulin signalling in Podocytes, induces insulin sensitivity, ameliorates renal dysfunction and alleviates diabetic kidney disease via down regulation of its target gene, 23/June/2017, 9.39 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.